Call on Wednesday, July 29th @ 1:30 p.m. Eastern Time; register here
Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opinion leader (KOL) and members of the Oncternal management team to discuss the current treatment landscape of mantle cell lymphoma (MCL) and updates on the use of cirmtuzumab to treat patients with MCL on Wednesday, July 29, 2020 at 1:30 p.m. Eastern Time.
The call will feature a scientific presentation on the current treatment landscape and unmet medical need in treating patients with MCL by Michael Wang, MD, professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. Dr. Wang, a consultant to Oncternal, will be available to answer questions at the conclusion of the call.
Oncternal's management team will also discuss the recently announced updates to the clinical program of cirmtuzumab, a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). Cirmtuzumab is currently in a Phase 1/2 clinical trial in combination with ibrutinib for treating patients with relapsed/refractory MCL and patients with CLL. After recently announced positive data in MCL presented at the American Society of Clinical Oncology 2020 Annual Meeting in May, the Company is amending the study to increase enrollment of MCL patients in the Phase 2 expansion cohort to at least 20 patients and to allow the enrollment of patients with a broader range of prior BTK inhibitor treatments.
To register for the call, click here.